## **EXHIBIT 24**

Seattle, WA

February 22, 2006

Page 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS IN RE: PHARMACEUTICAL ) INDUSTRY AVERAGE ) WHOLESALE PRICE LITIGATION )MDL Docket No. )Civil Action 01CV12257PBS DEPOSITION UPON ORAL EXAMINATION OF DOROTHY POULSEN 9:00 a.m February 22, 2006 PERKINS COIE 1201 Third Avenue, #4800 Seattle, Washington 98101 REPORTED BY: Judith A. Robinson, CCR #2171

February 22, 2006

Seattle, WA

Page 57

- be reimbursed our actual acquisition cost plus a fee
- equivalent to the amount we receive for other state
- facility prescriptions."
- <sup>4</sup> A. Right.
- <sup>5</sup> Q. Did you agree that the change to
- reimbursement methodology from AWP minus 10% to
- actual acquisition cost occur for MedManagement?
- $^8$  MR. LOPEZ: Object to the form.
- <sup>9</sup> THE WITNESS: Yes.
- BY MS. O'SULLIVAN:
- 11 Q. Is it fair to say, that as of this time in
- 1997, you understood that AWP minus 10% did not
- represent actual acquisition cost?
- 14 A. Yes.
- 15 Q. The court reporter has handed you Exhibit
- Poulsen 004 Bates numbered MT018455, a 1-page
- document dated July 30, 1997.
- Is this a letter that you sent to Al Stark
- of MedManagement?
- A. Yes, it is.
- Q. And comparing Exhibit Poulsen 003 to this
- document has Exhibit Poulsen 004, is this your

February 22, 2006

## Seattle, WA

Page 131

- have been \$16 or, you know, between \$8 and \$16 per
- prescription and we were paying \$4.20.
- When we used our methodology to determine
- what our dispensing fee should be, the amount we
- 5 came up with was invariably higher than what the
- 6 capped dispensing fee was. So virtually everyone had
- <sup>7</sup> the capped dispensing fee.
- <sup>8</sup> Q. Did you do the analysis that led to this
- 9 conclusion that the dispensing fee only covered one-
- quarter to one-half of the cost?
- A. I believe so.
- Q. Do you know where those dispensing fees
- are located at Montana Medicaid?
- A. In a file folder.
- Q. Who keeps that file?
- A. The pharmacy program officer or in
- archives. Or at this point in time, they may have
- done many things differently. But at the time I was
- doing it, it would have been in a file folder.
- Q. Based on this analysis that you did in
- Exhibit Poulsen 012, was it your understanding that
- Montana Pharmacy would lose money on every drug it

Seattle, WA

February 22, 2006

Page 132

- dispensed, unless it received some additional
- reimbursement from Medicaid?
- MR. LOPEZ: Objection.
- THE WITNESS: That was my rationale for
- paying them is AWP less 10%, rather than some other
- amount, is that otherwise, they would not be paid
- sufficiently to provide services to our clients.
- BY MS. O'SULLIVAN:
- <sup>9</sup> Q. Was it your understanding that the
- reimbursement methodology of AWP minus 10% was in
- part intended to make up for the lack of
- reimbursement for the dispensing fee?
- MR. LOPEZ: Objection.
- THE WITNESS: That was my assumption.
- When I came into the position, this was a system
- $^{16}$  that was set up. This was how it was set up. What I
- then tried to determine or figure out over the years
- is why we would set things up this way. So that was
- my understanding is we paid this way because -- I'm
- not sure which is the chicken and which is the egg.
- Did we pay a low dispensing fee because we thought
- that they were making money on the drug? Or did we